FINWIRES · TerminalLIVE
FINWIRES

Yasuda Logistics to Book 5.02 Billion Yen Gain from Hulic Share Sale

By

Yasuda Logistics (TYO:9324) expects to record a gain of 5.02 billion yen on the sale of investment securities as extraordinary income in the first quarter of the fiscal year ending March 31, 2027, according to a Tokyo bourse filing on Friday.

This gain follows the company's decision to sell 3.11 million common shares of Hulic (TYO:3003) as part of a secondary offering, with a total sale amount of 5.02 billion yen or 1,615.26 yen per share.

Although the gain has been partially factored into the consolidated forecasts announced on May 8, the company is leaving its full-year projections unchanged at this time.

Related Articles

Asia

Jiajia Food Amends Investment Fund Agreement

Jiajia Food Group (SHE:002650) signed a supplemental agreement with general partner Hexing Tianjin Equity Investment Fund, amending cash management and stabilization fund rules, according to a Friday fling with the Shenzhen bourse.The partnership, in which Jiajia holds a 99.995% stake as a limited partner with 200 million yuan invested, will now allow low-risk cash management activities including government bonds, money market funds and stable bank products.The amendment eliminates the requirement to reserve 20% of exit proceeds as a stabilization fund, enabling full distribution of exit proceeds to partners.Shares of the condiment food products company closed 1% higher Friday.

$SHE:002650
Asia

Ascent Bridge Forecasts Net Loss in Fiscal 2026

Ascent Bridge (SGX:AWG) is expecting to book a net loss for the fiscal year ended March 31, according to a Thursday filing with the Singapore Exchange.Shares of the global beverage alcohol distributor were down over 1% in Friday trading.The company has attributed its net loss to decreased revenue due to reduced contributions from duty-free markets.

$SGX:AWG
Asia

Guangdong Hybribio Biotech Subsidiary Gets China Approval for Norovirus Detection Kit

China's drug regulator approved the norovirus in vitro diagnostic reagents manufactured by Guangdong Hybribio Biotech (SHE:300639) subsidiary Guangzhou KBP Pharmaceutical, according to a Friday filing with the Shenzhen bourse.The reagent detects norovirus GⅠ, GⅡ and GⅣ in human fecal samples, the filing said.Norovirus causes outbreaks of nonbacterial and foodborne acute gastroenteritis in humans, and causes sporadic diarrhea.The virus is also the second leading cause of diarrhea in infants and children aged five years and under, the company said.

$SHE:300639